MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze MDXG →
    • FindStock Picks / Stock Screener
    • Value · MDXGIntrinsic Value Calculator
    • Invest · MDXGInvestment Case
    • Hold · MDXG5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
MDXG stock logo

MDXG

MiMedx Group, Inc.

$3.05
-0.06
 (-1.93%)
Exchange:  NASDAQ
Market Cap:  445.073M
Shares Outstanding:  147.793M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Joseph H. Capper
Full Time Employees:  808
Address: 
1775 West Oak Commons Court, NE
Marietta
GA
30062
US
Website:  https://www.mimedx.com
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.’s main office is located in Marietta, Georgia.

Click to read more…

Revenue Segmentation

Revenue by type

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

MDXG full analysis

30/10/2025

Welcome to MARKETSNAP’s SWOT analysis for MiMedx Group, a player in the biotech space that might not be on everyone’s radar just yet. If you’re a long-term investor looking to uncover potential gems in the healthcare sector, stick with me as we dive into what makes MiMedx tick, break down their strengths, weaknesses, opportunities, and threats, and figure out if this stock deserves a spot in your portfolio. First, let’s get a quick lay of the land. MiMedx Group operates…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
MDMDXG logoMDXGMiMedx Group, Inc.445.1M——-9.7%
DMDMAC logoDMACDiaMedica Therapeutics Inc.445.1M——-143.8%
CTCTMX logoCTMXCytomX Therapeutics, Inc.442.5M——-29.7%
CACAPR logoCAPRCapricor Therapeutics, Inc.439.6M——-50.8%
ANANL logoANLAdlai Nortye Ltd.453.8M——-9.2%
STSTTK logoSTTKShattuck Labs, Inc.454.2M——-36.8%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/28 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue321,477348,879418,630
Gross Profit266,843288,806345,617
EBITDA40,51765,35282,926
Operating Income37,11658,86563,887
Net Income67,43942,41948,578

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets239,047263,915342,653
Total Liabilities96,33070,80886,105
Total Stockholders Equity142,717193,107256,548
Total Debt48,09924,8421,500
Cash and Cash Equivalents82,000104,416166,121

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow26,77566,19874,003
Capital Expenditure-1,987-1,683-1,033
Free Cash Flow24,78864,51572,970
Net Income67,43941,99848,578
Net Change in Cash16,05022,41661,705

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)417,593.926Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)433,794.234Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)423,600Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)53,877.085Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)56,124.545Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)54,710.469Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)39,679.989Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)41,690.789Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)40,425.617Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)297,208.619Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)308,738.651Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)301,483.243Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.270Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.280Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.270Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
348.879M  ?P/S
 (TTM)
: 
1.54
?Net Income
 (TTM)
: 
42.419M  ?P/E
 (TTM)
: 
-24.69
?Enterprise Value
 (TTM)
: 
347.63M  ?EV/FCF
 (TTM)
: 
17.07
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-8.29%  ?ROIC
 (TTM)
: 
-9.73%
?Net Debt
 (TTM)
: 
-79.574M  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
2.22  ?Current Ratio
 (TTM)
: 
4.35

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Robust Revenue Growth: MiMedx reported a 13% revenue increase in Q2 2025, as highlighted in the earnings call transcript, reflecting strong demand for its product portfolio and effective market penetration within the healthcare sector.
  • Solid Financial Position: Key metrics indicate a healthy current ratio (TTM) and quick ratio (TTM), suggesting strong liquidity to meet short-term obligations. Additionally, positive free cash flow (TTM) supports operational stability and potential reinvestment.
  • Strong Product Portfolio: The earnings call emphasized MiMedx's ability to leverage its product offerings, positioning the company as a leader in its niche within the biotechnology industry, as supported by revenue product segment data.
  • Market Presence and Adaptability: The earnings call transcript notes MiMedx's capability to adapt to evolving reimbursement landscapes, underpinned by a strong market presence, which enhances its competitive edge.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates MDXG intrinsic value between $7.22 – $10.43 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate MDXG Intrinsic Value

Common questions about MDXG valuation

Is MiMedx Group, Inc. (MDXG) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for MiMedx Group, Inc. (MDXG) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is MDXG a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MDXG trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is MDXG’s P/E ratio?

You can see MDXG’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for MDXG?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is MDXG a good long-term investment?

Whether MDXG fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for MiMedx Group, Inc.

  • MiMedx Group, Inc. intrinsic value calculatorEstimate what the business is worth
  • MiMedx Group, Inc. 5-year outlookWhat has to go right, and what could go wrong
MDXG

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.93
MarketSnap

Trading Metrics:

Open: 3.09   Previous Close: 3.11
Day Low: 3.03   Day High: 3.14
Year Low: 3.03   Year High: 7.45
Price Avg 50: 4.14   Price Avg 200: 4.13
Volume: 2.12M   Average Volume: 1.385M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze MDXG →
    • FindStock Picks / Stock Screener
    • Value · MDXGIntrinsic Value Calculator
    • Invest · MDXGInvestment Case
    • Hold · MDXG5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.